S. Enatsu

发表

Possible applications of antibodies or their genes in cancer therapy.

M. Kuroki, Jian Huang, Toshihiro Tanaka, 2006, Anticancer research.

Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY

J. Shih, Keunchil Park, C. Chiu, 2020, Cancer science.

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC

K. Nishio, S. Ikeda, A. Zimmermann, 2022, JTO clinical and research reports.

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

J. Shih, Keunchil Park, S. Novello, 2019, The Lancet. Oncology.

A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors

K. Suzukawa, Ling Gao, T. Tamura, 2017, Japanese journal of clinical oncology.

Pleural lavage cytology before and after lung resection in non-small cell lung cancer patients.

Y. Nishiwaki, K. Nagai, J. Yoshida, 2006, The Annals of thoracic surgery.

Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor.

A. Iwasaki, T. Shirakusa, Y. Yoshinaga, 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

The impact on survival of positive intraoperative pleural lavage cytology in patients with non-small-cell lung cancer.

Y. Nishiwaki, K. Nagai, G. Ishii, 2010, The Journal of thoracic and cardiovascular surgery.

Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer.

I. Okamoto, K. Nakagawa, K. Yonesaka, 2010, Lung cancer.

Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors

R. Kurek, T. Tamura, Yasuhide Yamada, 2016, Cancer Chemotherapy and Pharmacology.

Long-term Pemetrexed Administration in 22 Patients with Non-small Cell Lung Cancer in a Japanese Phase II Randomized Study

K. Matsui, Y. Nambu, S. Enatsu, 2009 .

Dose-escalation study of thoracic radiotherapy in combination with pemetrexed plus Cisplatin followed by pemetrexed consolidation therapy in Japanese patients with locally advanced nonsquamous non-small-cell lung cancer.

Y. Ohe, K. Kubota, K. Nihei, 2013, Clinical lung cancer.

Is T2 non-small cell lung cancer located in left lower lobe appropriate to upstage?

A. Iwasaki, T. Shirakusa, Y. Yoshinaga, 2005, Interactive cardiovascular and thoracic surgery.

Results of surgical treatment for non-small cell lung cancer of 20 mm or less in diameter.

A. Iwasaki, T. Shirakusa, S. Enatsu, 2004, The Thoracic and cardiovascular surgeon.

Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT

M. Ahn, J. Yang, R. Cheng, 2014, Cancer research and treatment : official journal of Korean Cancer Association.

Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (≤20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours)

H. Iwasaki, K. Nabeshima, M. Kikuchi, 2005, Histopathology.

Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma.

M. Kuroki, T. Kawakami, A. Iwasaki, 2007, Anticancer research.

Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Review of Results from an Open-Label Randomized Phase II Study

N. Saijo, Y. Nishiwaki, M. Fukuoka, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials

G. Sledge, H. Iwata, M. Goetz, 2021, Cancer science.

Surgical treatment for lung cancer with COPD based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD).

A. Iwasaki, T. Shirakusa, Y. Yoshida, 2005, The Thoracic and cardiovascular surgeon.

Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: A subgroup analysis of elderly patients.

K. Suzukawa, M. Nishio, I. Okamoto, 2019, Respiratory investigation.

Non-small cell lung cancer, locally advanced

P. Lambin, S. Kozlov, I. Petersen, 2012 .

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset

Y. Ohe, K. Kiura, K. Goto, 2021, JTO clinical and research reports.

P3.01-75 RELAY+, an Exploratory Study of Gefitinib with Ramucirumab in Untreated Patients with EGFR Mutation-Positive Metastatic NSCLC

K. Nishio, K. Suzukawa, M. Nishio, 2018, Journal of Thoracic Oncology.

Clinical evaluation of systemic inflammatory response syndrome (SIRS) in advanced lung cancer (T3 and T4) with surgical resection.

T. Maekawa, A. Iwasaki, T. Shirakusa, 2005, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

J. Shih, Keunchil Park, S. Novello, 2019, Journal of Clinical Oncology.

Targeting of cancer gene therapy with antibodies or their genes against tumor-associated antigens

M. Kuroki, Jian Huang, M. Kuroki, 2005 .

Randomized phase 2 trial of gefitinib with and without pemetrexed as first-line therapy in East Asian patients with advanced, epidermal growth factor receptor (EGFR) mutation-positive (mt+), nonsquamous (NS) non-small cell lung cancer (NSCLC): Translational research and interim overall survival (OS)

P-C. Yang, Y. Cheng, H. Murakami, 2016 .

Overexpression of IQGAP1 in advanced colorectal cancer correlates with poor prognosis—critical role in tumor invasion

Y. Yamashita, H. Iwasaki, K. Nabeshima, 2010, International journal of cancer.

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.

Hiroshi Yasui, Ken Huang, N. Raje, 2009, Blood.

Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma

P. Richardson, N. Raje, T. Hideshima, 2008, British journal of haematology.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan.

Y. Hosomi, Y. Ohe, K. Suzukawa, 2019, Lung cancer.

A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutation: Final Overall Survival and Biomarker Analysis.

Tuan S. Nguyen, Ying Cheng, Pan‐Chyr Yang, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.

Ying Cheng, Pan‐Chyr Yang, J. Yang, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.

Y. Hosomi, Y. Ohe, K. Yoh, 2016, Lung cancer.

RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC).

K. Nishio, S. Ikeda, A. Zimmermann, 2020 .

A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies

H. Ohmatsu, K. Yoh, Hideaki Takahashi, 2016, Investigational New Drugs.

Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan

S. Enatsu, H. Ishiguro, Z. Cai, 2019, Breast cancer.

Expression of hypoxia-inducible factor-1 alpha and its prognostic significance in small-sized adenocarcinomas of the lung.

M. Kuroki, H. Iwasaki, K. Nabeshima, 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

S. Kudoh, Masashi Takahashi, S. Noma, 2017, Japanese journal of clinical oncology.

Gefitinib with or without pemetrexed in nonsquamous (NS) non-small cell lung cancer (NSCLC) with EGFR mutation (mut): Final overall survival (OS) results from a randomized phase II study.

P-C. Yang, Y. Cheng, J. Kim, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.